VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Winshear Gold Corp. ("Winshear" or the "Company") (TSXV:WINS) hereby reports that the Company held its Annual General Meeting on Monday October, 20, 2025 (all materials circulated for the AGM can be accessed here). All matters were approved unanimously. Further, the Board of Directors of the Company approved the issuance of 1,600,000 incentive stock options to Directors, Officers and consultants. The options have an exercise price of $0.13 per s ...

Core Viewpoint - Tango Therapeutics, Inc. has announced a significant underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $210 million to support its precision cancer medicine initiatives [1] Group 1: Offering Details - The offering consists of 21,023,337 shares of common stock priced at $8.66 each and pre-funded warrants to purchase up to 3,226,458 shares priced at $8.659 each [1] - The gross proceeds from the offering are expected to be around $210 million before deducting underwriting discounts and commissions [1] - The offering is expected to close on or about October 24, 2025, subject to customary closing conditions [1] Group 2: Private Investment in Public Equity (PIPE) - Concurrently, Tango has entered into a PIPE agreement, selling 1,732,101 shares at the same price of $8.66 per share, with expected gross proceeds of approximately $15 million [3] - The PIPE is led by Nextech and is also expected to close on or about October 24, 2025, subject to customary closing conditions [3] Group 3: Management and Regulatory Information - Leerink Partners and Cantor are acting as joint bookrunning managers for the offering [2] - The offering is made pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [4] - The securities sold in the PIPE are not registered under the Securities Act of 1933 and will require a registration statement for resale [5] Group 4: Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and developing precision medicine for cancer treatment [7] - The company utilizes the genetic principle of synthetic lethality to target critical areas in cancer, including tumor suppressor gene loss [7]

Core Viewpoint - Altisource Portfolio Solutions S.A. reported solid financial performance for the third quarter of 2025, with growth in service revenue and improvements in earnings metrics compared to the same period in 2024 [2][5]. Company Financial Performance - Service revenue for Q3 2025 was $39.7 million, an increase of $1.5 million or 4% from Q3 2024 [5][6]. - The net loss attributable to Altisource was $2.4 million, representing a $7.0 million improvement compared to the same quarter of 2024 [5][6]. - Diluted loss per share improved to $(0.22), a $2.39 improvement from the same quarter in 2024 [5][6]. - Adjusted EBITDA for Q3 2025 was $3.6 million, roughly flat compared to Q3 2024, with an adjusted EBITDA margin of 9.1%, down from 9.5% in the same quarter of 2024 [5][6]. - The company ended the quarter with $28.6 million in cash and cash equivalents [5]. Business Segments Performance - Adjusted EBITDA in the Servicer and Real Estate and Origination segments improved to $10.9 million, or 27.5% of service revenue, compared to $10.8 million, or 28.3% of service revenue in Q3 2024 [5]. - The company generated sales wins estimated to represent potential annualized service revenue of $3.2 million for the Servicer and Real Estate segment and $11.2 million for the Origination segment [5][6]. Industry Context - Industrywide foreclosure initiations were 19% higher for the eight months ended August 31, 2025, compared to the same period in 2024 [5]. - Industrywide mortgage origination volume increased by 17% for the nine months ended September 30, 2025, driven by a 4% decline in purchase origination and a 103% increase in refinancing origination [5].

Core Viewpoint - Codexis, Inc. will report its financial results for Q3 2025 on November 6, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Codexis is a leading provider of enzymatic solutions aimed at efficient and scalable manufacturing of complex therapeutics, utilizing its proprietary CodeEvolver technology platform [3]. - The company is developing the ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route [3]. - Codexis' enzymes are designed to address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, offering benefits such as higher yields, reduced energy usage, and improved efficiency [3].

Core Viewpoint - The Joint Corp. will report its third quarter 2025 financial results on November 6, 2025, with a conference call scheduled for the same day to discuss the results [1]. Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S. through The Joint Chiropractic network, having introduced a retail healthcare business model in 2010 [4]. - The company operates over 950 locations nationwide and records more than 14 million patient visits annually, positioning itself as a leader in the chiropractic industry [4]. - The Joint has received multiple accolades, including being named "No. 1 in Chiropractic Services" by Entrepreneur and consistently ranking in Franchise Times' annual lists [4]. Business Structure - The Joint Corp. functions as both a franchisor and operator of clinics in various states, providing management services to affiliated chiropractic practices in numerous locations [5].

Core Insights - Noma and Novonesis are collaborating to enhance food flavors and create healthier products by merging culinary arts with bioscience [1][3][4] Company Collaboration - The partnership aims to unite influential chefs and leading scientists to translate lab innovations into culinary experiences [3][7] - Noma's founder, René Redzepi, emphasizes the importance of flavor in inspiring new eating habits and unlocking new culinary possibilities [4][6] Innovation and Approach - Noma utilizes fermentation to develop unique flavors, while Novonesis brings over 100 years of fermentation expertise to the collaboration [4][5] - The partnership focuses on local ingredients and community preferences, with Novonesis adjusting taste profiles using biosolutions [5][6] Product Development - The collaboration will explore new flavors, textures, and nutritional profiles, aiming to create products that are healthier and more flavorful [7] - Initial products from this partnership will be showcased at Gulfood Manufacturing in Dubai from November 4-6 [7]

Core Viewpoint - The Simply Good Foods Company reported solid financial results for fiscal year 2025, with net sales increasing by 9% and a focus on integrating the OWYN acquisition while navigating inflationary pressures and evolving consumer habits [2][11][12]. Financial Performance - For the fourth quarter of fiscal year 2025, net sales were $369.0 million, a decrease of 1.8% year-over-year, primarily due to a 6.9% headwind from lapping an extra week in the previous year [3][6]. - Organic net sales growth was 3.5%, with the OWYN acquisition contributing $5.6 million, or 1.5%, to reported net sales growth [3][11]. - Gross profit for the fourth quarter was $126.6 million, down 13.3% from the previous year, with a gross margin of 34.3%, reflecting a 450 basis point decrease due to elevated input costs [5][12]. Operating Expenses - Operating expenses increased to $138.4 million, up $40.3 million year-over-year, with selling and marketing expenses decreasing by $8.4 million due to planned reductions for the Atkins brand [7][13]. - General and administrative expenses were $40.6 million, slightly down from the previous year, with a notable decrease in costs excluding integration expenses [7][13]. Net Income and Earnings - The company reported a net loss of $12.4 million for the fourth quarter, compared to a net income of $29.3 million in the prior year, resulting in a loss per diluted share of $0.12 [6][9]. - Adjusted EBITDA for the fourth quarter was $66.2 million, a decrease of 14.5% from $77.5 million in the previous year [9][10]. Fiscal Year 2025 Summary - For the full fiscal year 2025, net sales reached $1,450.9 million, a 9% increase driven by a 7.9% contribution from the OWYN acquisition and 3.0% organic growth [11][15]. - Gross profit for the year was $525.7 million, up 2.8% year-over-year, with a gross margin of 36.2%, reflecting a decrease of 220 basis points due to inflationary pressures [12][15]. Balance Sheet and Cash Flow - At the end of fiscal year 2025, the company had cash of $98.5 million and a term loan balance of $250.0 million, having repaid over $200.0 million of its debt during the year [18][19]. - Cash flow from operations was approximately $178.5 million, down from $215.7 million in the previous year, primarily due to higher working capital needs [19]. Outlook for Fiscal Year 2026 - The company anticipates a balanced outlook for fiscal year 2026, with expectations for net sales growth between -2% and +2% year-over-year and a decline in gross margins by 100 to 150 basis points [24][21]. - Increased marketing spending is planned for Quest and OWYN, with expectations for stronger performance in the second half of the fiscal year [21][22].

Core Insights - Tango Therapeutics announced positive data from its Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers, particularly pancreatic cancer, showing a median progression-free survival (mPFS) of 7.2 months and an objective response rate (ORR) of 25% in the second-line setting [1][2] Efficacy Results Across Study Indications - The overall ORR across 16 cancer types in the trial is 27% with a disease control rate (DCR) of 78% and a median PFS of 6.4 months [5] - In the histology-agnostic cohort, the ORR is 49% with a mPFS of 9.1 months, excluding sarcoma [11] Efficacy Results in Pancreatic Cancer Patients - For pancreatic cancer specifically, the ORR in second-line patients is 25%, while the ORR for all pancreatic cancer patients is 15% [5][11] - The DCR for all pancreatic cancer patients is reported at 71% [11] Development Strategy in Pancreatic Cancer - The company plans to initiate a global, randomized, pivotal study in 2026 comparing vopimetostat to standard chemotherapy regimens in patients with MTAP-deleted pancreatic cancer who have received one prior line of therapy [11] - The ongoing combination study with RAS(ON) inhibitors is expected to provide initial data in 2026 [11] Safety and Tolerability - Vopimetostat is generally well tolerated at the agreed dose of 250 mg QD, with common treatment-related adverse events including nausea (26%), anemia (20%), and fatigue (19%) [8] - No treatment-related Grade 4 or 5 events occurred, and only 8% of patients required dose reduction [8] About Vopimetostat - Vopimetostat is a potentially best-in-class oral PRMT5 inhibitor targeting cancers with MTAP deletion, which occurs in 10-15% of all human cancers, including 35% of pancreatic cancer [12] About Tango Therapeutics - Tango Therapeutics is focused on discovering novel drug targets and developing precision medicine for cancer treatment, leveraging the genetic principle of synthetic lethality [13]

In 2026, Arco Vara will release its consolidated financial reports on the following dates: 26.02.2026: Q4 2025 unaudited interim report16.04.2026: 2025 audited annual report30.04.2026: Q1 2026 unaudited interim report30.07.2026: Q2 2026 unaudited interim report29.10.2026: Q3 2026 unaudited interim report. Darja BolshakovaCFOArco Vara ASdarja.bolshakova@arcovara.com ...

TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce that it has entered into an Investor Relations Agreement with Mr. Eduardo “Ed” Baer, a seasoned mining executive with over 30 years of experience in corporate development, capital markets, and investor communications within the mining sector. Mr. Baer has held senior executive positions with European Goldfields Ltd., TVX Gold Inc., and Greystar Resources Ltd., and has led numerou ...